Skip to content

Protective effect of compound danshen drip pill on acute myocardial infarction reperfusion injury

Protective effect of compound danshen drip pill on acute myocardial infarction reperfusion injury

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000365
Enrollment
Unknown
Registered
2025-02-19
Start date
2024-05-07
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myocardial infarction

Interventions

Compound Danshen Dropping Pills Group :Compound danshen drip pill oral or sublingual 10 pills each time 3 times a day 4 weeks for a course of treatment.
Conventional drug treatment group:Conventional drug

Sponsors

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Age greater than 18 years old and not greater than 80 years old (2) Clinical diagnosis meets the 2019 Chinese diagnostic criteria for acute ST-segment elevation myocardial infarction (3) Patients with onset time less than 12 hours or greater than 12 hours but still meet the criteria for emergency coronary intervention; and proposed to undergo PCI surgery (4) Signed the informed consent form

Exclusion criteria

Exclusion criteria: (1) Haemodynamic instability (2) Severe hepatic and renal insufficiency; (3) Inability to tolerate long-term antiplatelet therapy; (4) Patients with previous myocardial infarction or myocardial damage (5) those with a life expectancy of less than 1 year (6) those who have undergone coronary artery bypass grafting (7) Those with metal allergies or contraindications to DES implantation (8) Patients who in the opinion of the investigator are not suitable for participation in this study

Design outcomes

Primary

MeasureTime frame
myocardial infarction area;Left Ventricular End-Systolic Diameter;Microvascular Obstruction;Left Ventricular End-Diastolic Diameter;Ejection Fraction;Fractional Shortening;Intramyocardial Hemorrhage/Myocardial edema area;

Secondary

MeasureTime frame
ST segment fallback time;Interleukin 6;soluble growth stimulation expressed gene 2 protein;high-sense C react protein;Myocardial enzyme creatine kinase isoenzyme peak and time;ST segment fallback range;Interleukin 1ß;Tumour necrosis factor alpha;

Countries

China

Contacts

Public ContactXiaolong Wang

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

wangxl1965@126.com+86 135 0199 1450

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026